Sequenom Inc (SQNM) 4.52 $SQNM
Sequenom Announces 2015 First Quarter Results Conference Call
PR Newswire - Wed Apr 22, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a leading molecular diagnostics company, today announced it will report financial results for the first quarter 2015 after closing of the NASDAQ Global Market on Wednesday, May 6, 2015.
SQNM: 4.52 (-0.10)
Sequenom (SQNM) Looks Good: Stock Gains 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:04AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise over 6% on the day.
SQNM: 4.52 (-0.10), AEZS: 0.57 (unch)
Why Sequenom (SQNM) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 7:53AM CDT
Sequenom is one such company that might be well-positioned for future earnings growth as it saw EPS growth of 63.6% last year, and is looking great for this year too.
SQNM: 4.52 (-0.10)
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 4.52 (-0.10), APRI: 1.61 (-0.13)
Insiders Seeing Green With SQNM At New 52-Week High
MarketNewsVideo.com - Mon Apr 13, 12:27PM CDT
In trading on Monday, shares of Sequenom Inc touched a new 52-week high of $4.37/share. That's a 82.08% rise, or $1.97 per share from the 52-week low of $2.40 set back on 04/15/2014.
SQNM: 4.52 (-0.10)
Stock to Watch: Sequenom Up 6.6% (SQNM)
Comtex SmarTrend(R) - Mon Apr 13, 10:37AM CDT
Sequenom (NASDAQ:SQNM) is one of today's best performing low-priced stocks, up 6.6% to $4.24 on 2.2x average daily volume. Sequenom has traded 2.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.2%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
SQNM: 4.52 (-0.10)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
Recombine Announces Launch of Its CarrierMap(TM) Carrier Screening Test Through Sequenom
Business Wire - Mon Mar 30, 8:00AM CDT
Recombine, Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, announced a partnership with Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:SQNM), a leading life sciences company, to expand access to Recombine's CarrierMap test beyond the fertility and in-vitro fertilization (IVF) setting. Sequenom will market the test under the name HerediT(R) UNIVERSAL.
SQNM: 4.52 (-0.10)
Life Sciences Tools and Services Equities Technical Coverage -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and Affymetrix
PR Newswire - Fri Mar 27, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
GENE: 4.70 (-0.13), SQNM: 4.52 (-0.10), TMO: 130.02 (+0.47), A: 42.49 (-0.13), AFFX: 12.44 (-0.16)
Sequenom Laboratories To Present At ACMG Meeting
PR Newswire - Tue Mar 24, 3:30PM CDT
Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it will be presenting six scientific posters on noninvasive prenatal testing (NIPT) and supporting a continuing medical education (CME) satellite symposium through an unrestricted educational grant at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, which will be held March 24-28, 2015 in Salt Lake City, Utah.
SQNM: 4.52 (-0.10)
Sequenom Laboratories Launches The HerediT® UNIVERSAL Test In Collaboration With Recombine
PR Newswire - Thu Mar 19, 4:30PM CDT
Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, today announced the launch of the HerediT® UNIVERSAL carrier screening test as a service to ordering physicians. The launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.
SQNM: 4.52 (-0.10)
Kenneth Buechler Elected Chairman of Sequenom Board of Directors
PR Newswire - Tue Mar 17, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its Board of Directors elected Kenneth Buechler, Ph.D. as Chairman of the Board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, Jr., Ph.D. who will retire from the position effective March 31, 2015, after 11 years of service.
SQNM: 4.52 (-0.10)
Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents
Business Wire - Mon Mar 16, 3:05AM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced that it and its wholly-owned subsidiary, Verinata Health Inc., (together "Illumina"
have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.
SQNM: 4.52 (-0.10), ILMN: 189.59 (-3.01)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.41 (-2.95), PCYC: 256.59 (-0.51), ITEK: 5.61 (+0.86), REDX: (), PTX: 7.09 (-0.24), CLDX: 30.10 (+0.19), ILMN: 189.59 (-3.01), IDGX: (), ACAD: 38.36 (-0.54), TRGT: 2.43 (+0.04), CLLS: 32.61 (-0.07), EXAC: 24.40 (+0.15), ABBV: 66.07 (+1.82), CRMD: 8.61 (-0.22), AGMX: (), ZGNX: 1.54 (-0.11), VVUS: 2.46 (-0.04), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), OREX: 7.36 (-0.08), SQNM: 4.52 (-0.10), IRWD: 15.10 (-0.38), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), OHRP: 2.94 (+0.12), TEVA: 64.41 (+1.16)
CAROLYN BEAVER of Sequenom Inc. (SQNM)-Nasdaq bought Shares of SQNM
M2 - Wed Mar 11, 9:49AM CDT
Reported by InsiderCow.com at 2015-03-10 13:01:57 ET
SQNM: 4.52 (-0.10)
Looking Back At 2014 And What To Expect In 2015 For Sequenom
Doug Van Cuyk - at Seeking Alpha - Mon Mar 09, 2:59AM CDT
SQNM: 4.52 (-0.10), ILMN: 189.59 (-3.01)
Sequenom Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 10:07AM CST
SQNM: 4.52 (-0.10)
SEQUENOM (SQNM) William J. Welch on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 10:39PM CST
SQNM: 4.52 (-0.10)
Sequenom tops 4Q profit forecasts
Automated Insights - Wed Mar 04, 4:18PM CST
SAN DIEGO (AP) _ Sequenom Inc. (SQNM) on Wednesday reported fourth-quarter net income of $18.3 million, after reporting a loss in the same period a year earlier.
SQNM: 4.52 (-0.10)
Sequenom EPS of $0.14
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:14PM CST
SQNM: 4.52 (-0.10)
Sequenom Announces 2015 First Quarter Results Conference Call
PR Newswire - Wed Apr 22, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a leading molecular diagnostics company, today announced it will report financial results for the first quarter 2015 after closing of the NASDAQ Global Market on Wednesday, May 6, 2015.
SQNM: 4.52 (-0.10)
Sequenom (SQNM) Looks Good: Stock Gains 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:04AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise over 6% on the day.
SQNM: 4.52 (-0.10), AEZS: 0.57 (unch)
Why Sequenom (SQNM) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 7:53AM CDT
Sequenom is one such company that might be well-positioned for future earnings growth as it saw EPS growth of 63.6% last year, and is looking great for this year too.
SQNM: 4.52 (-0.10)
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 4.52 (-0.10), APRI: 1.61 (-0.13)
Insiders Seeing Green With SQNM At New 52-Week High
MarketNewsVideo.com - Mon Apr 13, 12:27PM CDT
In trading on Monday, shares of Sequenom Inc touched a new 52-week high of $4.37/share. That's a 82.08% rise, or $1.97 per share from the 52-week low of $2.40 set back on 04/15/2014.
SQNM: 4.52 (-0.10)
Stock to Watch: Sequenom Up 6.6% (SQNM)
Comtex SmarTrend(R) - Mon Apr 13, 10:37AM CDT
Sequenom (NASDAQ:SQNM) is one of today's best performing low-priced stocks, up 6.6% to $4.24 on 2.2x average daily volume. Sequenom has traded 2.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.2%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
SQNM: 4.52 (-0.10)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
Recombine Announces Launch of Its CarrierMap(TM) Carrier Screening Test Through Sequenom
Business Wire - Mon Mar 30, 8:00AM CDT
Recombine, Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, announced a partnership with Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:SQNM), a leading life sciences company, to expand access to Recombine's CarrierMap test beyond the fertility and in-vitro fertilization (IVF) setting. Sequenom will market the test under the name HerediT(R) UNIVERSAL.
SQNM: 4.52 (-0.10)
Life Sciences Tools and Services Equities Technical Coverage -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and Affymetrix
PR Newswire - Fri Mar 27, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
GENE: 4.70 (-0.13), SQNM: 4.52 (-0.10), TMO: 130.02 (+0.47), A: 42.49 (-0.13), AFFX: 12.44 (-0.16)
Sequenom Laboratories To Present At ACMG Meeting
PR Newswire - Tue Mar 24, 3:30PM CDT
Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it will be presenting six scientific posters on noninvasive prenatal testing (NIPT) and supporting a continuing medical education (CME) satellite symposium through an unrestricted educational grant at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, which will be held March 24-28, 2015 in Salt Lake City, Utah.
SQNM: 4.52 (-0.10)
Sequenom Laboratories Launches The HerediT® UNIVERSAL Test In Collaboration With Recombine
PR Newswire - Thu Mar 19, 4:30PM CDT
Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, today announced the launch of the HerediT® UNIVERSAL carrier screening test as a service to ordering physicians. The launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.
SQNM: 4.52 (-0.10)
Kenneth Buechler Elected Chairman of Sequenom Board of Directors
PR Newswire - Tue Mar 17, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its Board of Directors elected Kenneth Buechler, Ph.D. as Chairman of the Board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, Jr., Ph.D. who will retire from the position effective March 31, 2015, after 11 years of service.
SQNM: 4.52 (-0.10)
Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents
Business Wire - Mon Mar 16, 3:05AM CDT
Illumina, Inc. (NASDAQ:ILMN) today announced that it and its wholly-owned subsidiary, Verinata Health Inc., (together "Illumina"
have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. SQNM: 4.52 (-0.10), ILMN: 189.59 (-3.01)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.41 (-2.95), PCYC: 256.59 (-0.51), ITEK: 5.61 (+0.86), REDX: (), PTX: 7.09 (-0.24), CLDX: 30.10 (+0.19), ILMN: 189.59 (-3.01), IDGX: (), ACAD: 38.36 (-0.54), TRGT: 2.43 (+0.04), CLLS: 32.61 (-0.07), EXAC: 24.40 (+0.15), ABBV: 66.07 (+1.82), CRMD: 8.61 (-0.22), AGMX: (), ZGNX: 1.54 (-0.11), VVUS: 2.46 (-0.04), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), OREX: 7.36 (-0.08), SQNM: 4.52 (-0.10), IRWD: 15.10 (-0.38), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), OHRP: 2.94 (+0.12), TEVA: 64.41 (+1.16)
CAROLYN BEAVER of Sequenom Inc. (SQNM)-Nasdaq bought Shares of SQNM
M2 - Wed Mar 11, 9:49AM CDT
Reported by InsiderCow.com at 2015-03-10 13:01:57 ET
SQNM: 4.52 (-0.10)
Looking Back At 2014 And What To Expect In 2015 For Sequenom
Doug Van Cuyk - at Seeking Alpha - Mon Mar 09, 2:59AM CDT
SQNM: 4.52 (-0.10), ILMN: 189.59 (-3.01)
Sequenom Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 10:07AM CST
SQNM: 4.52 (-0.10)
SEQUENOM (SQNM) William J. Welch on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 10:39PM CST
SQNM: 4.52 (-0.10)
Sequenom tops 4Q profit forecasts
Automated Insights - Wed Mar 04, 4:18PM CST
SAN DIEGO (AP) _ Sequenom Inc. (SQNM) on Wednesday reported fourth-quarter net income of $18.3 million, after reporting a loss in the same period a year earlier.
SQNM: 4.52 (-0.10)
Sequenom EPS of $0.14
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:14PM CST
SQNM: 4.52 (-0.10)
